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ABSTRACT
The effects of type 2 diabetes mellitus (T2DM) on bone volumetric density, bone geometry, and estimates of bone strength are not well
established.Weusedperipheralquantitativecomputedtomography(pQCT)tocomparetibialandradialbonevolumetricdensity(vBMD,
mg/cm
3), total (ToA, mm
2) and cortical (CoA, mm
2) bone area and estimates of bone compressive and bending strength in a subset
(n¼1171) of men ( 65 years of age) who participated in the multisite Osteoporotic Fractures in Men (MrOS) study. Analysis of
covariance–adjusted bone data for clinic site, age, and limb length (model 1) and further adjusted for body weight (model 2) were used
tocomparedata betweenparticipants with(n¼190)andwithout (n¼981)T2DM.Atboth thedistaltibia andradius, patientswith T2DM
had greater bone vBMD (þ2% to þ4%, model 1, p<.05) and a smaller bone area (ToA  1% to  4%, model 2, p<.05). The higher vBMD
compensated for lower bone area, resulting in no differences in estimated compressive bone strength at the distal trabecular bone
regions.Atthemostlycorticalbonemidshaftsitesoftheradiusandtibia,menwithT2DMhadlowerToA( 1%to 3%,p<.05),resulting
in lower bone bending strength at both sites after adjusting for body weight ( 2% to  5%, p<.05) despite the lack of difference in
corticalvBMD atthese sites. Thesedata demonstrate thatoldermenwithT2DMhavebonestrength that islowrelativetobody weight at
the cortical-rich midshaft of the radius despite no difference in cortical vBMD.  2010 American Society for Bone and Mineral Research.
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Introduction
O
bservational cohort studies have found that type 2 diabetes
mellitus (T2DM) is associated with a 50% to 80% increased
risk of hip fracture, as well as a 30% to 70% increased risk of
fracture of the proximal humerus and foot.
(1–3) Although there is
awareness of the higher fracture rates among diabetic adults,
(4,5)
there are few data available on the factors responsible for this
increased risk. Identifying these factors is a critical step in the
development of potential interventions to prevent fractures
among the growing segment
(6) of the adult population with
T2DM.
Most, but not all, cross-sectional studies have found average
or even somewhat higher areal bone mineral density (aBMD,
g/cm
2) assessed by dual x-ray absorptiometry (DXA) in patients
with T2DM compared with healthy controls, even after
accounting for larger body size among diabetics.
(7–9) These
results are somewhat surprising given the increased fracture risk
associated with T2DM. However, DXA studies that use aBMD as
an outcome have several limitations. Measurement of aBMD
essentially assumes that bone is an amorphous solid, for which
size, shape, and the distribution of bone material within are
irrelevant. For example, DXA-measured bone density does not
account for bone dimensional changes or allow for separation of
the cortical and trabecular bone compartments. This may be
important in adults with T2DM for two reasons: (1) trabecular
bone, which is disproportionately affected by T2DM,
(10) may not
be detected by DXA, and (2) bone strength can be reduced even
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285when there are no changes (or even an increase) in aBMD because
of geometric changes.
(11) Other factors may influence bone
strength in diabetics, including changes in bone material proper-
ties (i.e., enzymatic and nonenzymatic cross-links
(12)), but bone
material properties per se cannot be measured noninvasively.
(13)
A 3D imaging technique, peripheral quantitative computed
tomography (pQCT), has allowed for assessment of volumetric
density of both cortical and trabecular compartments, as well as
structural estimates of bone strength derived from cross-
sectional geometry.
(14,15) This technology has the potential to
better classify skeletal properties. Few clinical studies have
examined bone properties other than aBMD in patients with
T2DM. Human studies exploring the association between T2DM
and bone parameters other than aBMD have focused on spine
bone volumetric BMD
(16,17) but have not reported bone
geometric parameters or estimates of cortical and trabecular
bone strength. However, animal studies suggest that bone
propertiesarecompromisedinratswithT2DM,
(10,18)highlighting
the importance of assessing these properties in humans.
The primary objective of this study was to examine the
association between T2DM and bone volumetric density,
geometry, and estimates of bone strength in community-
dwelling older men. We hypothesized that men with T2DM
would have lower bone strength relative to their body weight,
particularly in highly trabecular regions such as the distal radius
and distal tibia.
Methods
Participants
From March 2000 through April 2002, 5995 men who were at
least65yearsofagewereenrolledinthebaselineexaminationof
the prospective Osteoporotic Fractures in Men (MrOS) study.
(19)
Men were recruited from population-based listings in six areas of
the United States: Birmingham, Alabama, Minneapolis, Minne-
sota, Palo Alto, California, the Monongahela Valley near
Pittsburgh, Pennsylvania, Portland, Oregon, and San Diego,
California.
(19,20) Men with a history of bilateral hip replacement
and men who were unable to walk without the assistance of
anotherpersonwereexcluded.Theinstitutionalreviewboardsof
each center approved the study protocol, and written consent
was obtained from all participants.
Men who returned for their second exam an average of
4.7 0.4 years later were invited to participate in an ancillary
study involving pQCT. Of the 1550 men who attended the
second exam at the Pittsburgh and Minneapolis study sites, 1171
(76%) completed the clinic visit and agreed to participate in the
pQCT ancillary study and are included in this analysis. This
ancillary study was approved by the institutional review boards
at the Minneapolis and Pittsburgh sites. All participants in the
ancillary study signed a written informed consent for the pQCT
portion of the study.
Peripheral quantitative computed tomography
measurements
Peripheral quantitative computed tomography (pQCT) was used
to obtain slices (2.3 0.2mm) at the 4% and 66% sites of the left
tibia and at 4% and 33% of the nondominant forearm (radius).
Slices are taken as a percentage of limb length from the distal
end of the relevant bone. The XCT 2000 device (Stratec, Inc.,
Pforzheim, Germany) and the XCT-3000 device (Stratec, Inc.,
Pforzheim,Germany) wereused toobtainthe scans inPittsburgh
and Minneapolis, respectively. The only difference between the
2000 and 3000 scanners is the gantry size. The same acquisition
and analysis software was used toanalyze scans at both sites. We
performed a precision study using a European forearm phantom
scanned three times at each site at 200, 100, and 50mg/cc,
respectively. Values on the two instruments were similar and
within less tha 0.5% for total area at all mg/cc values and from
0.5% to 1.0% for total density.
Voxel size was 0.5mm, and the scan speed was 25mm/s. The
anatomic reference line (distal edge of the tibial plafond) was
determined by acquisition of a 30mm planar scout view of the
joint line. Data were analyzed according to the manufacturer’s
specifications. At the trabecular 4% sites, Contour mode
2 (169mg/cm
3) and Peel mode 1 (45% area) were used. Distal
sites were assessed for total bone cross-sectional area
(ToA, mm
2) and total density (ToD, mg/mm
3). Bone strength
index(BSI,mg/mm
4)wascalculatedas(ToA ToD
2)/1,000,000as
an index of bone compressive strength. At the more cortical
33% radius and 66% tibia sites, we used Contour mode
2 (169mg/cm
3) to determine whole bone properties and
Cortmode 1 (710mg/cm
3) for cortical bone properties. A
threshold of 280mg/cm
3 was used to determine the polar
strength strain index (SSIp). At these cortical sites, we assessed
total bone cross-sectional area (ToA, mm
2), cortical area
(CoA, mm
2), and cortical density (CoD, mg/mm
3). Polar strength
strain index (SSIp, mm
3) and section modulus (mm
3) were
calculated as estimates of bone bending strength,
(15) and muscle
cross-sectionalarea(MCSA,mm
2)wasmeasured(atthe66%tibia
only). SSIp is a ‘‘density-weighted’’ section modulus value,
whereas section modulus includes only geometric properties.
An anthropomorphic phantom was scanned daily for quality
assurance at both sites.
Dual energy x-ray absorptiometry
Total body, lumbar spine (L1 to L4), and total femur aBMD and
body composition (total body lean mass and total body fat mass)
were measured at the second exam using a fan-beam dual-
energyX-rayabsorptiometry(QDR4500W,Hologic,Inc.,Bedford,
MA, USA). Standardized procedures for participant positioning
and scan analysis were executed for all scans. All DXA operators
were centrally certified on the basis of an evaluation of scanning
and analysis techniques. Cross-calibration studies performed
priortothe baselineMrOSvisitfound nolineardifferences across
scanners, and the maximum percentage difference in mean total
spine BMD between scanners was 1.4%.
(21) Longitudinal quality
control using daily scan data for standardized phantoms at each
site indicated no shifts or drifts in scanner performance.
Health history, lifestyle, and demographic data
Information on demographics, medical and family history, and
lifestylewereobtainedbyquestionnaireandinterviewbytrained
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(white/nonwhite) was collected.
Presence or absence of T2DM was assessed by a self-report of
physician diagnosis of diabetes or current use (at exam 2) of
diabetes prescription medications, including hypoglycemics,
sulfonylureas, or insulin. Fasting glucose and A1C assays were
not available at exam 2.
Weight was measured in indoor clothing without shoes using
a calibrated balance beam or digital scale. Height was measured
using a Harpenden stadiometer (DyFed, UK), and body mass
index was calculated (kg/m
2). Prior to pQCT measurements, tibia
and forearm length were measured to the nearest millimeter
with an anthropometric tape measure. Tibia length was
measured from the tibial plateau to the medial malleolus, and
forearm length was measured from the ulnar styloid process to
the olecranon process. The mean of two measurements for each
variable was used for the analysis.
Tests of physical performance are included as descriptive
variables.Gaitspeedwasdeterminedasusualtimetocompletea
6m course and expressed in meters per second. Time to
complete five chair stands (seconds) and ability to stand from a
chair without using arms (yes/no) also were recorded. Grip
strength was measured twice by a handheld dynamometer
(Jamar) in both the left and right arms.
(22) The average grip
strength in kilograms was used in this analysis.
For lifestyle factors, men were classified into current, past, or
never smokers using data collected from their current and
baseline exams. Physical activity was measured by computing
the Physical Activity Summary Scale for the Elderly (PASE).
(23)
Statistical analyses
Differences in characteristics according to T2DM status were
compared using analysis of variance for normally distributed
continuous data and chi-square tests for categorical data.
Bone measures were expressed as continuous variables using
linear regression models, and the least-squared means proce-
dure was used to estimate the mean (95% confidence interval)
for each bone parameter by T2DM status (yes/no). Data are
presented for two models first adjusted for age groups (65 to 69,
70 to 74, 75 to 79, 80þ), race and tibia/radial length (model 1),
and an additional model with further adjustment for body
weight (model 2). Additional models wererun substituting either
leanmassorfatmassorbodymassindexinsteadofbodyweight,
and results were similar (data not shown). Therefore, only results
from models 1 and 2 are presented.
Results
Baseline descriptive characteristics
A total of 1171 participants had pQCT scans and complete visit
data at either the Minnesota (n¼540) or Pittsburgh (n¼631)
MrOs sites, 16% (n¼190) of whom had T2DM. A majority of men
in both groups were Caucasian (98%), with 1% of participants
being African American and 1% multiracial/other. Men with and
without T2DM were similar in age, height, and tibia and radius
length (Table 1). As expected, those with T2DM were heavier
(þ6.2kg, p<.001) and had a significantly higher average BMI
(þ2.3kg/m
2, p<.001). Diabetic participants also had higher
absolutelevelsoftotalbody leanandfatmass(see Table1)anda
slightly higher percent of body weight from fat mass
(28.7 5.4vs. 27.0 5.2, p<.001). Men with diabetes also were
significantly less active, had a lower grip strength, and took
longer to complete the chair stand (see Table 1). Slightly more
than half the men with T2DM were taking statins compared with
slightly less than half the men without T2DM. As reported
previously for the whole MrOS cohort,
(24) men with diabetes had
significantly higher aBMD measuredby DXA atall measuredsites
(þ4% to þ8%, p<.05 for all sites).
pQCT bone outcomes
Tibia
Tibial bone density, geometry, and strength estimates from
model 1 (adjusting for age, race, clinic site, and tibial length) and
Table 1. Descriptive and Functional Characteristics of 1171 Older Men by Diabetes Status
Type 2 diabetes No diabetes p
N 190 981
Age (years) 76.9 4.8 77.3 5.2 .394
Caucasian (%) 98 98 .802
Height (cm) 173 6.4 173 7.0 .392
Weight (kg) 89.1 14.9 82.9 13.0 <.001
Body mass index (kg/m
2) 29.9 4.5 27.6 3.8 <.001
Total body lean mass (kg) 60.8 7.8 57.8 7.4 <.001
Total body fat mass (kg) 25.6 8.0 22.4 6.8 <.001
PASE score 124.7 65.1 144.7 65.6 <.001
Maximum grip strength (kg) 38.6 7.8 41.0 8.0 <.001
Time to complete five chair stands (s) 12.3 3.5 11.4 3.4 .002
Unable to complete chair stands without using hands (%) 20% 7% <.001
Statins (%) 56% 43% <.001
Tibia length (mm) 400.2 27.3 402.9 25.7 .210
Radius length (mm) 284.2 18.5 283.8 16.1 .790
Values are mean SD unless otherwise noted.
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Table 2. At the highly trabecular distal tibia (4% site), diabetic
participants tended to have a smaller total bone area ( 1% to
 3%) but higher bone tissue density (þ1% to þ3%). Differences
weresignificantfordensitybeforeweightadjustments(p¼.025)
and for total area after adjusting for weight (p¼.007). The
slightly greater density in diabetics compensated for lower bone
area, so there was no difference in estimates of compressive
bonestrength(BSI)betweengroupsatthissiteafteradjustingfor
body weight (p¼.591, model 2; see Table 2).
Participants with diabetes also tended to have smaller total
bone area ( 1% to  2%) at the cortical 66% site of the tibia,
which was significantly different only after adjusting for body
weight (p¼.031). Cortical area was similar between groups both
before and after adjusting for body weight. Cortical bone density
wasnotdifferentbetweengroupsatthissiteineithermodel.The
smaller total bone area translated to a lower bone bending
strength (section modulus,  2.8%, p¼.033) after adjusting for
body weight. SSIp also tended to be lower in men with diabetes
after adjusting for body weight ( 2.5%) but was not significantly
different (p¼.106). Prior to adjusting for body weight, however,
there was no difference in section modulus (p¼.819) or SSIp
between groups (p¼.636). Diabetic participants also had
significantly larger muscle CSA (model 1, p¼.002), although
the muscle size was appropriate for their higher body weight
(model 2, p¼.841).
Radius
Boneparameters at the radius followed a similar pattern as those
at the tibia (Table 3). At the distal trabecular site, diabetics again
tended to have a smaller bone area ( 3% to  4%) and higher
bone density (þ3% to þ4%), but there was no difference in
compressive bone strength after adjusting for weight (p¼.284).
Differences in volumetric density were significant both before
(p¼.012) and after (p¼.029) adjusting for body weight,
whereas total area differences reached significance only after
adjusting for body weight (p¼.003). At the cortical 33% site,
bone strength again was significantly lower relative to body
weight (SSIp,  5.2%, p<.001; section modulus,  4.5%, p¼.002)
in men with T2DM because total ( 3.4%, p¼.002) and cortical
( 2.8%, p¼.019) bone areas were significantly smaller after
adjusting for body weight. Cortical bone density was not
different between groups in either model. Again, bone strength
was not different prior to adjusting for body weight (see Table 3,
model 1).
Discussion
We examined bone volumetric density, geometry, and estimates
of bone strength at cortical and trabecular sites of peripheral
bones in older men by T2DM status. Contrary to our hypothesis,
we found that estimated compressive bone strength was not
lower in the trabecular regions of men with T2DM. However,
bone strength was compromised in more cortical regions
relative to body weight in diabetics. In trabecular regions, a
higher bone tissue density compensated for the lower bone area
in diabetics, resulting in a lack of difference in estimates of
compressive bone strength at these sites. In contrast, the smaller
bone area (i.e., smaller periosteal circumference) among men
with T2DM translated to lower bone bending strength (relative
to body weight) in cortical regions of the tibia and radius.
What are the implications of the differences in
bone strength?
Epidemiologic studies suggest that patients with T2DM are at
increased risk of hip, foot, and ankle fractures despite having
Table 2. Tibial Bone Volumetric Density, Geometry, and Strength in Older Men by Diabetes Status
Model 1 (adjusted for age, race, clinic site,
and tibia length)
Model 2 (adjusted for age, race, clinic site,
tibia length, and body weight)
Type 2 diabetes No diabetes Type 2 diabetes No diabetes
4% Tibia
Total area (mm2)a 1273 (1249–1297) 1284 (1274–1295) 1252 (1228–1276) 1288 (1278–1298)
 
Total density (mg/cm3)a 305 (298–312) 297 (294–300)
  303 (296–310) 297 (294–300)
Trabecular density (mg/cm
3)
a 237 (231–243) 229 (227–232)
  235 (229–241) 230 (227–232)
BSI
a,b 120 (115–125) 114 (112–116)
  116 (111–121) 115 (113–117)
66% Tibia
Total area (mm
2)
a 763 (749–776) 768 (762–773) 753 (740–767) 769 (764–775)
 
Cortical area (mm
2)
a 338 (330–346) 334 (330–337) 330 (322–337) 336 (332–339)
Cortical density (mg/cm
3)
a 1060 (1055–1065) 1064 (1061–1066) 1060 (1054–1065) 1064 (1061–1066)
pSSI (mm
3)
a 3397 (3319–3476) 3377 (3343–3411) 3323 (3247–3399) 3391 (3359–3424)
Section modulus (mm
3)
b 3386 (3304–3468) 3375 (3340–3411) 3298 (3219–3377) 3392 (3358–3426)
 
Muscle CSA
c 7723 (7566–7879) 7455 (7387–7524)
  7486 (7347–7626) 7502 (7442–7562)
Values are mean (95% confidence intervals).
BSI¼(total area total density
2)/1,000,000.
Significantly different from diabetes group;
 P<.05;
  P<.001.
aN¼1135.
bN¼1132.
cN¼1124.
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DXA.
(3,9,25) The higher aBMD persists even after adjusting for
body weight in most studies. As a result, the focus of fracture risk
in T2DM is often on increased risk of falls. Indeed, patients with
diabetes may have an increased risk of falls owing to
complications from comorbidities associated with T2DM. For
example, impaired vision and peripheral neuropathy are
common complications of T2DM—which may compromise
vision and proprioception, respectively, and subsequently
increase risk of falls.
(26,27) In our population, older men with
T2DM showed reduced muscular strength and neuromuscular
function, which also might increase the risk of falls.
Nevertheless, the risk of fracture is a function of both the load
ontheboneduringthefallandthestrengthofboneitself.
(28)Our
datademonstratethatestimatesofbonestrengthatcorticalsites
are low relative to body weight in patients with T2DM. In
previous studies demonstrating higher aBMD in type 2 diabetics,
the higher DXA aBMD values might be explained by the smaller
bone area in men with diabetes—that is, an equivalent amount
of bone material within a smaller bone area would show up as a
higher aBMD when measured by DXA.
(17,29) However, because
bone bending strength increases as bone is distributed further
from the neutral axis, this smaller bone area (and higher aBMD)
can translate to a lower bone bending strength.
(29) Although
indices of bone bending bone strength (section modulus and
SSIp) among men with T2DM in our population were normal in
an absolute sense (i.e., prior to adjusting for body weight), the
section modulus was low for body weight, which might increase
the risk of fracture in the case of a fall.
Other insults to the mechanical competence of bone, not
measurable noninvasively in humans, have been demonstrated
in T2DM. For instance, Saito and colleagues
(12) demonstrated
age-related changes in enzymatic and nonenzymatic cross-links
ofbonecollageninthespontaneouslytype2diabeticratwithout
a decrease in aBMD. This study suggested that alterations in
collagen properties may make bone of type 2 diabetics more
susceptible to fracture and, paired with our findings, demon-
strates the importance of studying both bone strength and falls
risk in T2DM.
What could cause the differences in bone density and
geometry in diabetics?
Several factors could influence bone properties in diabetic
patients, including altered mechanical load, adipose-derived
hormones, hyperglycemia, and/or pharmaceutical treatment,
(30)
as well as other diabetic complications such as renal failure,
(31)
microvascular complications, and peripheral neuropathy,
(32)
Consistent with the general type 2 diabetic population, a
majority of the men in our population with T2DM were
overweight (45% BMI > 25) or obese (44% BMI > 30). There
is some confusion in the literature as to the effects of excessive
body weight on bone mass and strength. A high body weight
generally is considered to be protective of bone mechanical
competence largely based on DXA data that consistently show
high aBMD in overweight and obese adults.
(33) As reported in
nondiabetic overweight children and adults,
(34–36) the older men
with T2DM in our study had high absolute bone strength—but
thatstrengthwaslowonceadjustedfortheirhigherbodyweight
despite similar cortical bone volumetric density.
Excess body weight affects bone not only via mechanical
pathways but also through secretion of hormones from adipose
tissue. These adipose-derived hormones (e.g., leptin, adiponec-
tin, and resistin) have conflicting effects on bone metabolism.
(30)
For example, serum leptin levels have been positively correlated
and serum adiponectin levels have been negatively correlated
with aBMD of the hip, lumbar spine, and distal radius,
(37,38)
whereas resistin may stimulate osteoclastogenesis.
(39) Although
we did not measure adipose-derived hormones in this study, it is
possiblethatserumelevationsinthesehormoneswouldpartially
explain the smaller periosteal diameter (represented by total
bone area) at the midshaft of the tibia and radius in type 2
Table 3. Radial Bone Volumetric Density, Geometry, and Strength in Older Men by Diabetes Status (95% Confidence intervals)
Model 1 (adjusted for age, race, clinic site,
and radius length)
Model 2 (adjusted for age, race, clinic site,
radius length, and body weight)
Type 2 diabetes No diabetes Type 2 diabetes No diabetes
4% Radius
Total area (mm
2) 379 (368–389) 390 (385–394) 374 (363–384) 391 (386–395)
 
Total density (mg/cm
3) 364 (354–373) 350 (346–354)
  362 (352–372) 350 (346–355)
 
Trabecular density (mg/cm
3) 205 (198–211) 195 (193–198)
  203 (197–210) 196 (193–199)
 
BSI
  50 (48–53) 48 (47–49)
  49 (47–52) 48 (47–49)
33% Radius
Total area (mm
2) 143 (140–146) 146 (144–147) 141 (138–144) 146 (145–147)
 
Cortical area (mm
2) 104 (102–107) 105 (104–106) 103 (101–105) 106 (105–107)
 
Cortical density (mg/cm
3) 1158 (1153–1163) 1160 (1158–1162) 1160 (1155–1165) 1159 (1157–1162)
Strength strain index (mm
3) 355 (345–365) 364 (360–369) 349 (339–358) 365 (361–370)
 
Section modulus (mm
3) 348 (338–358) 356 (351–360) 341 (332–350) 357 (353–361)
 
Values are mean.
BSI¼index of compressive bone strength [(total area total density
2)/1,000,000],
Significantly different from diabetes group;
 p<.05;
  p 0.001.
N¼1126 for models at 4% radius; N¼1122 for models at 33% radius.
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hormones would preferentially impact the periosteal surface. In
contrast, mechanical loading has been demonstrated to add
bone to the periosteal surface at the midshaft of long bones.
(40)
Therefore, the larger bone diameter in nondiabetics could reflect
the higher physical activity level. While these theories remain be
tested in this population, it is unclear why our findings are in
contrast with animal data showing increased periosteal diameter
in a type 2 diabetic rat model.
(10,18)
At the distal trabecular regions of the tibia and radius, bone
densitywassignificantlyhigherinpatientswithdiabetes.Wehad
hypothesized that trabecular bone density would be compro-
mised owing to data showing that, in animals, T2DM primarily
impacts trabecular bone.
(10,18) Owing to the increased body
weight, we speculated that diabetics would have a wider bone
areaatthedistalsiteandthusrequirealowerdensitytomaintain
mechanical competence. In contrast, older men in our
population with diabetes had an increased bone density and
smaller bone area at the trabecular sites. Data from Krakauer and
colleagues
(7) may help to explain these findings. These authors
demonstrated low bone turnover in six participants with T2DM
from histologic data from transiliac bone biopsies.
(7) A lower
bone turnover in this population may help to explain the higher
volumetric density at the highly trabecular distal sites in
diabetics. Our findings are also congruent with bone histomor-
phometric studies of diabetic animal models that have found
significantly impaired bone formation and decreased mineraliz-
ingsurfaceandmineralappositionrateindiabeticratscompared
with healthy controls.
(41) (Liu, 2007, #3460) Low bone turnover,
coupled with impaired bone formation, may explain our findings
of low bone area and greater vBMD in this population. However,
pQCT has limited resolution and is unable to assess trabecular
thickness or connectivity. Studies using higher-resolution
instruments are needed to further explore these findings.
It is also possible that hormonal, nutritional, or pharmaceutical
factors or other diabetic complications (e.g., renal failure) that we
did not measure may have influenced our findings. For instance,
the majority of our participants were on some form of diabetes
medication. While metformin may have a positive effect on
bone,
(42) adverse effects of a group of diabetic drugs (i.e.,
thiazolidinediones) also has been demonstrated in humans.
(43,44)
In addition, renal failure is associated with altered bone
properties
(45) and is a common complication of T2DM. Our data
were not powered to adequately explore the effects of different
medications, but future research should incorporate anti-
diabetic drug use and other mediating factors when interpreting
the effects of T2DM on bone strength.
Strengths and limitations
There are several strengths to our study, including the unique
focusonoldermen.Althoughitisestimatedthatoneinfourmen
will experience an osteoporotic fracture in their lifetime, few
studies have focused on risk factors for osteoporosis and fracture
in older men. Another strength of the current study was the
assessment of volumetric BMD, bone geometry, and structural
strength estimates that allowed for characterization of the
underpinnings of bone strength differences in older men with
and without T2DM. There are, however, several factors we could
not address adequately that may have influenced our results. In
particular, the duration or severity of diabetes were not assessed.
We did not have information on the disease duration and were
unable to adequately assess disease severity owing to a lack of
hemoglobin A1C outcomes at exam 2. In our sample, there were
no clear differences between men taking insulin versus other
hypoglycemics (data not shown). However, we had a relatively
small sample size in each strata, with only 27 men taking insulin.
In addition, low testosterone and growth hormone levels are
associated with T2DM and may influence bone stiffness.
(46) As
with any cross-sectional study, our data show associations only
and cannot prove causation. Future prospective studies should
explore the role of disease duration and severity on bone
outcomes and include assessment of hormonal factors.
Importantly, a majority of the sample were white men, so we
are not able to generalize results to other ethnic populations.
Finally, a potential source of bias is the self-report diagnosis of
diabetes. However, a majority of participants who self-identified
as having T2DM also were on relevant medication.
Summary and Conclusions
While past studies have demonstrated greater aBMD in T2DM,
the current study, using pQCT, showed that type 2 diabetics had
low bone strength for body weight at predominantly cortical
sites. These findings, combined with the propensity to fall, may
help to explain the increased risk of fracture in patients with type
2 diabetes.
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